Lexaria Bioscience (LEXX) EBIT (2017 - 2026)
Lexaria Bioscience (LEXX) posted EBIT of -$2.0 million for Q2 2026, down 37.32% sequentially from -$1.5 million in Q1 2026, and up 46.84% YoY from -$1.4 million in Q2 2025.
Lexaria Bioscience (LEXX) EBIT (2017 - 2026) Analysis & Trends
Lexaria Bioscience has reported EBIT for 10 years, with the latest figure at -$2.0 million in Q2 2026.
- Quarterly EBIT rose 46.84% year-over-year to -$2.0 million in Q2 2026, while the trailing twelve-month figure through May 2026 was -$7.7 million (up 32.36% YoY) and the FY2025 annual result came in at -$11.9 million, down 106.51% from the prior year.
- EBIT declined to -$2.0 million in Q2 2026 per LEXX's latest filing, from -$1.5 million in the prior quarter.
- Over five years, EBIT peaked at -$668005.0 in Q1 2024 and troughed at -$3.8 million in Q2 2025.
- A 5-year average of -$1.9 million and a median of -$1.7 million in 2022 frame the typical range for EBIT.
- The sharpest annual moves came in 2024 and 2025: EBIT jumped 49.53% in 2024, then tumbled 311.83% in 2025.
- Over 5 years, EBIT stood at -$1.7 million in 2022, then jumped by 32.81% to -$1.1 million in 2023, then tumbled by 136.2% to -$2.7 million in 2024, then surged by 41.52% to -$1.6 million in 2025, then fell by 26.7% to -$2.0 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$2.0 million, -$1.5 million, and -$1.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Lexaria Bioscience | 10.63 Mn | 7.01 Mn | - | -1.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -1.99 Mn |
| Feb 28, 2026 | -1.45 Mn |
| Nov 30, 2025 | -1.57 Mn |
| Aug 31, 2025 | -2.69 Mn |
| May 31, 2025 | -3.75 Mn |
| Feb 28, 2025 | -2.75 Mn |
| Nov 30, 2024 | -2.69 Mn |
| Aug 31, 2024 | -2.20 Mn |
| May 31, 2024 | -1.74 Mn |
| Feb 29, 2024 | -668,005.00 |
| Nov 30, 2023 | -1.14 Mn |
| Aug 31, 2023 | -1.11 Mn |
| May 31, 2023 | -2.40 Mn |
| Feb 28, 2023 | -1.32 Mn |
| Nov 30, 2022 | -1.70 Mn |
| Aug 31, 2022 | -748,547.00 |
| May 31, 2022 | -2.42 Mn |
| Feb 28, 2022 | -1.45 Mn |
| Nov 30, 2021 | -2.00 Mn |
| Aug 31, 2021 | -1.30 Mn |